Nuria Garcia Diaz

Utvalgte publikasjoner

Ortiz-Romero PL, Maroñas Jiménez L, Muniesa C, [...], García-Díaz N, Vega R, Lora D, Postigo C, Jiménez B, Sánchez-Beato M, Pedro Vaqué J, Rodríguez Peralto JL, de la Cámara AG, de la Cruz J, Piris Pinilla MÁ. Activity and safety of topical pimecrolimus in patients with early stage mycosis fungoides (PimTo-MF): a single-arm, multicentre, phase 2 trial. The Lancet Haematology 2022.

https://doi.org/10.1016/S2352-3026(22)00107-7

García-Díaz, N; Casar, B; Alonso-Alonso, R; Quevedo, L; [...]; Ortiz-Romero, PL; Piris, MA and Vaqué, JP. PLCγ1/PKCθ downstream signaling controls cutaneous T-cell lymphoma development and progression. Journal of Investigative Dermatology 2021. 

https://doi.org/10.1016/j.jid.2021.09.024

García-Díaz, N; Piris, MA; Ortiz-Romero, PL and Vaqué, JP. Mycosis fungoides and Sézary syndrome: diagnosis, molecular drivers and therapy. Cancers 2021. 

https://doi.org/10.3390/cancers13081931

Alonso-Alonso, R; Mondéjar, R; Martínez, N; García-Diaz, N; […]; Scholz, C; Vaqué, JP; Gualberto, A; Piris, MÁ. Identification of tipifarnib sensitivity biomarkers in T-cell acute lymphoblastic leukemia and T-cell lymphoma. Scientific Reports 2020. 

https://doi.org/10.1038/s41598-020-63434-5

Pérez, C; Mondéjar, R; García-Díaz, N; Cereceda, L; […]; Martínez, N; Vaqué, JP; Ortiz-Romero, PL; Piris, MA. Advanced-stage mycosis fungoides: role of the signal transducer and activator of transcription 3, nuclear factor-κB and nuclear factor of activated T cells pathways. British Journal of Dermatology 2019. 

https://doi.org/10.1111/bjd.18098

Ruso-Julve, F; Pombero, A; Pilar-Cuéllar, F; García-Díaz, N; […]; Gonzalez-Maeso, J; Martínez, S; Vaqué, JP; Crespo-Facorro, B. Dopaminergic control of ADAMTS2 expression through cAMP/CREB and ERK molecular effects of antipsychotics. Translational psychiatry 2019. 

https://doi.org/10.1038/s41398-019-0647-7

Llerena, S*; García-Díaz, N*; Curiel-Olmo, S; Agraz-Doblas, A; […]; Varela, I; Piris, MÁ; Crespo, J; Vaqué, JP.  Applied diagnostics in liver cancer. Efficient combinations of sorafenib with targeted inhibitors blocking AKT/mTOR. Oncotarget 2018. *Contributed equally. 

https://doi.org/10.18632/oncotarget.25766

Pérez, C; González-Rincón, J; Onaindia, A; Almaráz, C; García-Díaz, N; […]; Ortiz-Romero, P; Sánchez-Beato, M; Piris, MÁ; Vaqué, JP. Mutated JAK kinases and deregulated STAT activity are potential therapeutic targets in cutaneous T-cell lymphoma. Haematologica 2015. 

https://doi.org/10.3324/haematol.2015.132837

Curiel-Olmo, S; García-Castaño, A; Vidal, R; Pisonero, H; Varela, I; León-Castillo, A; Trillo, E; González-Vela, C; García-Díaz, N; […]; Ortiz-Romero, P; Valdizán, E; Piris, MA; Vaqué, JP. Individualized strategies to target specific mechanisms of disease in malignant melanoma patients displaying unique mutational signatures. Oncotarget 2015. 

https://doi.org/10.18632/oncotarget.4545